| (19) |
 |
|
(11) |
EP 4 385 520 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
11.09.2024 Bulletin 2024/37 |
| (43) |
Date of publication A2: |
|
19.06.2024 Bulletin 2024/25 |
| (22) |
Date of filing: 16.09.2016 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
19.09.2015 US 201514859292
17.06.2016 US 201615185564
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
16778870.2 / 3349784 |
| (71) |
Applicant: Ecole Polytechnique Fédérale de Lausanne |
|
1015 Lausanne (CH) |
|
| (72) |
Inventors: |
|
- HUBBELL, Jeffrey A.
1015 Lausanne (CH)
- WILSON, David Scott
1015 Lausanne (CH)
|
| (74) |
Representative: Zwicker, Jörk |
|
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München
80686 München (DE) |
|
| |
|
| (54) |
GLYCOTARGETING THERAPEUTICS |
(57) Several embodiments of the present disclosure relate to therapeutic compositions
configured to target the liver of a subject and that are useful in the treatment or
prevention of one or more of transplant rejection, autoimmune disease, food allergy,
and immune response against a therapeutic agent. In several embodiments, the compositions
are configured to target the liver and deliver antigens to which tolerance is desired.
In several embodiments, the compositions are configured for clearance of a circulating
protein or peptide or antibody associated with one or more of the above-mentioned
maladies. Methods and uses of the compositions for induction of immune tolerance are
also disclosed herein.